Our findings add to existing work by using finer measures of exposure (metformin use specifically rather than combining diabetes medications) and outcome (continuous density measures), by adjusting for insulin use—thought to be associated with increased MBD [24]—and by considering co-medications with statin. The gene discussed is INS; the disease is diabetes mellitus.